Vaccine design for severe acute respiratory syndrome coronavirus

Viral Immunology

Volumn 18, Issue 2, 2005, Pages 327-332

  He, Yuxian ^a   Jiang, Shibo ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INACTIVATED VIRUS VACCINE; NEUTRALIZING ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS SPIKE PROTEIN; VIRUS VACCINE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; BIOLOGICAL WARFARE; CONTROLLED STUDY; DRUG DESIGN; GENETIC ENGINEERING; HOST RANGE; IMMUNE RESPONSE; INFLAMMATION; MOUSE; NONHUMAN; PROTEIN DOMAIN; RECEPTOR BINDING; REVIEW; SARS CORONAVIRUS; VIRUS NEUTRALIZATION; VIRUS SPIKE;

ANIMALS; DRUG DESIGN; GENETIC VECTORS; HUMANS; MEMBRANE GLYCOPROTEINS; MICE; RABBITS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

ANIMALIA; CORONAVIRUS; SARS COV;

EID: 23344449892     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2005.18.327     Document Type: Review

References (57)

1. 2004. Trial watch: SARS vaccine enters Phase I trials. Expert Rev. Vaccines 3:386.
2. Babcock, G.J., D.J. Esshaki, W.D. Thomas, Jr., D.M. Ambrosino. 2004. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J. Virol. 78:4552-4560.
3. Bisht, H., A. Roberts, L. Vogel, et al. 2004. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U.S.A. 101:6641-6646.
4. Bonavia, A., B.D. Zelus, D.E. Wentworth, et al. 2003. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. J. Virol. 77:2530-2538.
5. Buchholz, U.J., A. Bukreyev, L. Yang, et al. 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci U.S.A. 101:9804-9809.
6. Bukreyev, A., E.W. Lamirande, U.J. Buchholz, et al. 2004. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363:2122-2127.
7. Cavanagh, D. 1995. The coronavirus surface glycoprotein. In: S.G. Siddell (ed.). The Coronaviridae. Plenum Press, New York, pp. 73-114.
8. Chen, Z., L. Zhang, C. Qin, et al. 2005. Recombinant modified vaccinia virus ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 79:2678-2688.
9. Corapi, W.V., C.W. Olsen, F.W. Scott. 1992. Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J. Virol. 66:6695-6705.
10. Cyranoski, D., A. Abbott. 2003. Virus detectives seek source of SARS in China's wild animals. Nature 423:467.
11. Dimitrov, D.S. 2003. The secret life of ACE2 as a receptor for the SARS virus. Cell 115:652-653.
12. Drosten, C., S. Gunther, W. Preiser, et al. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348:1967-1976.
13. Enserink, M. 2004. Infectious diseases. One year after outbreak, SARS virus yields some secrets. Science 304:1097.
14. Fleck, F. 2004. SARS virus returns to China as scientists race to find effective vaccine. Bull. WHO 82:152-153.
15. Fouchier, R.A., T. Kuiken, M. Schutten, et al. 2003. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423:240.
16. Frana, M.F., J.N. Behnke, L.S. Sturman, K.V. Holmes. 1985. Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: host-dependent differences in proteolytic cleavage and cell fusion. J. Virol. 56:912-920.
17. Godet, M., J. Grosclaude, B. Delmas, H. Laude. 1994. Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein. J. Virol. 68:8008-8016.
18. Guan, Y., B.J. Zheng, Y.Q. He, et al. 2003. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302:276-278.
19. He, Y., H. Lu, P. Siddiqui, et al. 2005. Receptor-binding domain of SARS coronavirus spike protein contains multiple conformational-dependant epitopes that induce highly potent neutralizing antibodies. J. Immunol 174:4908-4915.
20. He, Y., Y. Zhou, S. Liu, et al 2004. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324:773-781.
21. He, Y., Y. Zhou, P. Siddiqui, S. Jiang. 2004. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem. Biophys. Res. Commun. 325:445-452.
22. He, Y., Y. Zhou, H. Wu, et al. 2004. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J. Immunol. 173:4050-4057.
23. He, Y., Q. Zhu, S. Liu, et al. 2005. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334:74-82.
24. Holmes, K.V. 2003. SARS coronavirus: a new challenge for prevention and therapy. J. Clin. Invest. 111:1605-1609.
25. Ksiazek, T.G., D. Erdman, C.S. Goldsmith, et al. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348:1953-1966.
26. Kubo, H., Y.K. Yamada, F. Taguchi. 1994. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J. Virol. 68:5403-5410.
27. Lai, M.M., D. Cavanagh. 1997. The molecular biology of coronaviruses. Adv. Virus Res. 48:1-100.
28. Li, W., M.J. Moore, N. Vasilieva, et al. 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450-454.
29. Liang, G., Q. Chen, J. Xu, et al. 2004. Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg. Infect. Dis. 10:1774-1781.
30. Luytjes, W., L.S. Sturman, P.J. Bredenbeek, et al. 1987. Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site. Virology 161:479-487.
31. Marra, M.A., S.J. Jones, C.R. Astell, et al. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399-1404.
32. Marshall, E., M. Enserink. 2004. Medicine. Caution urged on SARS vaccines. Science 303:944-946.
33. Martina, B.E., B.L. Haagmans, T. Kuiken, et al. 2003. Virology: SARS virus infection of cats and ferrets. Nature 425:915.
34. Ng, S.K. 2003. Possible role of an animal vector in the SARS outbreak at Amoy Gardens. Lancet 362:570-572.
35. Nie, Y., G. Wang, X. Shi, et al. 2004. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J. Infect. Dis. 190:1119-1126.
36. Olsen, C.W., W.V. Corapi, R.H. Jacobson, et al. 1993. Identification of antigenic sites mediating antibody-dependent enhancement of feline infectious peritonitis virus infectivity. J. Gen. Virol. 74:745-749.
37. Peiris, J.S., S.T. Lai, L.L. Poon, et al. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319-1325.
38. Prabakaran, P., X. Xiao, D.S. Dimitrov. 2004. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem. Biophys. Res. Commun. 314:235-241.
39. Rota, P.A., M.S. Oberste, S.S. Monroe, et al. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399.
40. Saif, L.J. 1993. Coronavirus immunogens. Vet. Microbiol. 37:285-297.
41. Simmons, G., J.D. Reeves, A.J. Rennekamp, et al. 2004. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci U.S.A. 101:4240-4245.
42. Snijder, E.J., P.J. Bredenbeek, J.C. Dobbe, et al. 2003. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331:991-1004.
43. Spiga, O., A. Bernini, A. Ciutti, et al. 2003. Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein. Biochem. Biophys. Res. Commun. 310:78-83.
44. Stavrinides, J., D. S. Guttman. 2004. Mosaic evolution of the severe acute respiratory syndrome coronavirus. J. Virol. 78:76-82.
45. Sui, J., W. Li, A. Murakami, et al. 2004. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl. Acad. Sci U.S.A. 101:2536-2541.
46. Takasuka, N., H. Fujii, Y. Takahashi, et al. 2004. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunol. 16:1423-1430.
47. Tang, L., Q. Zhu, E. Qin, et al. 2004. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 23:391-394.
48. Vennema, H., R.J. de Groot, D.A. Harbour, et al. 1990. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 64:1407-1409.
49. Wang, D., J. Lu. 2004. Glycan arrays lead to the discovery of autoimmunogenic activity of SARS-CoV. Physiol. Genomics 18:245-248.
50. Wang, P., J. Chen, A. Zheng, et al. 2004. Expression cloning of functional receptor used by SARS coronavirus. Biochem. Biophys. Res. Commun. 315:439-444.
51. Wang, S., T.H. Chou, P.V. Sakhatskyy, et al. 2005. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J. Virol. 79:1906-1910.
52. Weingartl, H., M. Czub, S. Czub, et al. 2004. Immunization with modified Vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78:12672-12676.
53. Wong, S.K., W. Li, M.J. Moore, et al. 2004. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279:3197-3201.
54. Xiao, X., S. Chakraborti, A.S. Dimitrov, et al. 2003. The SARS-CoV S glycoprotein: expression and functional characterization. Biochem. Biophys. Res. Commun. 312:1159-1164.
55. Xiong, S., Y.F. Wang, M.Y. Zhang, et al. 2004. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol. Lett. 95:139-143.
56. Yang, Z.Y., W.P. Kong, Y. Huang, et al. 2004. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428:561-564.
57. Yang, Z.Y., H.C. Werner, W.P. Kong, et al. 2005. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci U.S.A. 102:797-801.